FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS

Ofer Mandelboim (Inventor), Angel Porgador (Inventor)

Research output: Patent

Abstract

The present invention relates generally to peptides derived from the natural cytotoxicity receptors on natural killer (NK) cells and to antibodies against peptide epitopes on these receptor. In particular, the present invention identifies an essential epitope in the proximal domain of NKp46 and NKp44 receptors present on NK cells, as a crucial element for the binding to viral-infected. The present invention provides peptides that are derived from the amino acid sequence of NKp46 receptor, capable of specific targeting of viral-infected cells and tumor cells and monoclonal antibodies which recognize a specific domain of NKp46. The present invention further provides hyperglycosylated peptides that are derived from the NKp44 receptor, capable of specific targeting of viral-infected cells.

Original languageEnglish
Patent numberWO2005000086
IPCC07K 14/ 705 A I
Priority date30/06/03
StatePublished - 6 Jan 2005

Fingerprint

Dive into the research topics of 'FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS'. Together they form a unique fingerprint.

Cite this